fda compounding semaglutide update The is proposing the removal of three GLP-1 drugs from the 503B bulks list of active ingredients that outsourcing facilities can use to make compounded medicines, the agency announced on Thursday The FDA Wins. The OFA

AbdellatifMTrummer-HerbstVKoserFDurandSAdoRVasques-NvoaFet al

Differences in Characteristics and Complications for GLP-1 Users Patients taking GLP-1 medications were more likely to have comorbidities including type 2 diabetes, hypertension, and chronic obstructive pulmonary disease, although body mass index was similar between groups

Thus, we speculated that T3 might regulate GLP-1 production in a cell-nonautonomous manner

S1, Fig

Existing research has suggested that kefiran intake has led an improvement in serum total cholesterol as observed in a study of high-cholesterol rabbits (Uchida et al., 2010).Medrano et al

To view or add a comment, sign in Glad to see decisive action from the FDA